Skip to content
Subscriber Only

Bayer Said to Weigh Plastics Unit Sale Amid Health Focus

Bayer AG’s possible sale of its $10 billion plastics unit would accelerate a retreat from chemicals that the maker of Aspirin initiated a decade ago, leaving it focused on the more lucrative life-science industry.

The German company is reviewing options for Bayer Material Science after chemicals company Evonik Industries AG showed potential interest some months ago, according to people with knowledge of the matter, who asked not to be identified because talks are private. No decision has been made, and Evonik’s considerations failed to gain traction, they said.